Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Mumps virus vaccine

Mary A Albrecht, MD
Section Editor
Martin S Hirsch, MD
Deputy Editor
Elinor L Baron, MD, DTMH


Mumps virus infection usually presents as a nonspecific prodrome consisting of low-grade fever, malaise, headache, myalgias, and anorexia. These symptoms are generally followed within 48 hours by the development of parotitis, the classic feature of mumps. Symptomatic infection in adults is usually more severe than that in children.

Mumps vaccine is effective in preventing mumps and its potential complications, including orchitis, aseptic meningitis, and pancreatitis. (See "Epidemiology, clinical manifestations, diagnosis, and management of mumps".)


There are five vaccine strains: Jeryl Lynn, Urabe, Rubini, Leningrad-Zagreb, and Leningrad-3 [1]. The World Health Organization has stated that all vaccine strains are acceptable for use, except Rubini because of its association with decreased protective efficacy [2,3]. The Jeryl Lynn–derived vaccine is currently used in the United States and the United Kingdom.

A trivalent measles-mumps-rubella vaccine was licensed for use in 1967. A tetravalent measles-mumps-rubella-varicella (MMRV; ProQuad) vaccine was licensed by the US Food and Drug Administration in September 2005 for use in children ages 12 months to 12 years [4,5]. This vaccine facilitates immunization against measles, mumps, rubella, and varicella with one injection.

Monovalent vaccines (eg, mumps, measles, or rubella) are no longer available [6].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Feb 10, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Peltola H, Kulkarni PS, Kapre SV, et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis 2007; 45:459.
  2. Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005; 51:294.
  3. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008; 47:1458.
  4. CDC. Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR Morb Mortal Wkly Rep 2005; 54:1212.
  5. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.
  6. Kimberlin DW, Bocchini JA. Monovalent vaccines no longer available for measles, mumps, rubella. AAP News 2009; 30:9.
  7. Centers for Disease Control and Prevention (CDC). Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR Morb Mortal Wkly Rep 2006; 55:629.
  8. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152:36.
  9. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.
  10. Peltola H, Jokinen S, Paunio M, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008; 8:796.
  11. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008; 358:1580.
  12. Mumps vaccine. MMWR Morb Mortal Wkly Rep 1977; 26:393.
  13. Centers for Disease Control and Prevention (CDC). Effectiveness of a seventh grade school entry vaccination requirement--statewide and Orange County, Florida, 1997-1998. MMWR Morb Mortal Wkly Rep 1998; 47:711.
  14. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.
  15. Weibel RE, Stokes J Jr, Buynak EB, et al. Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med 1967; 276:245.
  16. Hilleman MR, Weibel RE, Buynak EB, et al. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med 1967; 276:252.
  17. Vandermeulen C, Roelants M, Vermoere M, et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004; 22:2713.
  18. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169:77.
  19. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Recomm Rep 1995; 44:1.
  20. Anderson LJ, Seward JF. Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J 2008; 27:S75.
  21. Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine 2009; 27:446.
  22. Halperin SA, Ferrera G, Scheifele D, et al. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine 2009; 27:2701.
  23. Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008; 198:508.
  24. Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008; 46:1172.
  25. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008; 197:1662.
  26. LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552.
  27. Castilla J, García Cenoz M, Arriazu M, et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 2009; 27:2089.
  28. Cortese MM, Barskey AE, Tegtmeier GE, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis 2011; 204:1413.
  29. Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567.
  30. Hanna-Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis 2008; 197:1669.
  31. Vandermeulen C, Clement F, Roelants M, et al. Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. J Infect Dis 2009; 199:1457.
  32. King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704.
  33. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397.
  34. D'Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell 2000; 24:27.
  35. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767.
  36. Institute of Medicine. Measles and mumps vaccines. In: Adverse events associated with childhood vaccines. Evidence bearing on causality, Stratton KR, Howe CJ, Johnston RB (Eds), National Academy Press, Washington, DC 1994. p.118.
  37. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345:567.
  38. Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J 1996; 15:44.
  39. Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326.
  40. Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97:738.
  41. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341:979.
  42. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997; 16:500.
  43. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991; 10:209.
  44. Colville A, Pugh S. Mumps meningitis and measles, mumps, and rubella vaccine. Lancet 1992; 340:786.
  45. Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000; 151:524.
  46. Peltola H. Mumps vaccination and meningitis. Lancet 1993; 341:994.
  47. Rees J, Hughes R. Guillain-Barré syndrome after measles, mumps, and rubella vaccine. Lancet 1994; 343:733.
  48. Plesner AM, Hansen FJ, Taudorf K, et al. Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. Acta Paediatr 2000; 89:58.
  49. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.
  50. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 2008; 57:258.
  51. Hiltunen M, Lönnrot M, Hyöty H. Immunisation and type 1 diabetes mellitus: is there a link? Drug Saf 1999; 20:207.
  52. Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120:878.
  53. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.
  54. From the Centers for Disease Control and Prevention. Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19-35 months--United States, 1996. JAMA 1997; 278:622.
  55. Shaheen MA, Frerichs RR, Alexopoulos N, Rainey JJ. Immunization coverage among predominantly Hispanic children, aged 2-3 years, in central Los Angeles. Ann Epidemiol 2000; 10:160.